Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Martina D’Aronzo 1,* , Manlio Vinciguerra 1,2,3,* , Tommaso Mazza 4 , Concetta Panebianco 1 , Chiara Saracino 1 , Stephen P. Pereira 2 , Paolo Graziano 5 and Valerio Pazienza 1 1 Gastroenterology Unit, I.R.C.C.S. “Casa Sollievo della Sofferenza” Hospital San Giovanni Rotondo (FG), Italy 2 Institute for Liver and Digestive Health, Division of Medicine, University College London (UCL), London, United Kingdom 3 School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom 4 Bioinformatics Unit I.R.C.C.S. “Casa Sollievo della Sofferenza”, Istituto Mendel, Italy 5 Pathology Unit I.R.C.C.S. “Casa Sollievo della Sofferenza” Hospital San Giovanni Rotondo (FG), Italy * These authors have contributed equally to this work Correspondence to: Valerio Pazienza, email: // Keywords : pancreatic cancer, gemcitabine, hENT1 Received : January 16, 2015 Accepted : May 12, 2015 Published : May 19, 2015 Abstract Background/aims: Pancreatic cancer (PC) is ranked as the fourth leading cause of cancer-related deaths worldwide. Despite recent advances in treatment options, a modest impact on the outcome of the disease is observed so far. Short-term fasting cycles have been shown to potentiate the efficacy of chemotherapy against glioma. The aim of this study was to assess the effect of fasting cycles on the efficacy of gemcitabine, a standard treatment for PC patients, in vitro and in an in vivo pancreatic cancer mouse xenograft model. Materials and Methods: BxPC-3, MiaPaca-2 and Panc-1 cells were cultured in standard and fasting mimicking culturing condition to evaluate the effects of gemcitabine. Pancreatic cancer xenograft mice were subjected to 24h starvation prior to gemcitabine injection to assess the tumor volume and weight as compared to mice fed ad libitum . Results: Fasted pancreatic cancer cells showed increased levels of equilibrative nucleoside transporter (hENT1), the transporter of gemcitabine across the cell membrane, and decreased ribonucleotide reductase M1 (RRM1) levels as compared to those cultured in standard medium. Gemcitabine was more effective in inducing cell death on fasted cells as compared to controls. Consistently, xenograft pancreatic cancer mice subjected to fasting cycles prior to gemcitabine injection displayed a decrease of more than 40% in tumor growth. Conclusion: Fasting cycles enhance gemcitabine effect in vitro and in the in vivo PC xenograft mouse model. These results suggest that restrictive dietary interventions could enhance the efficacy of existing cancer treatments in pancreatic cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hucka, M., Finney, A., Sauro, H. M., Bolouri, H., Doyle, J. C., Kitano, H., Arkin, A. P., Bornstein, B. J., Bray, D., Cornish-Bowden, A., et al. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg015 · Cited by 3,060 · cited 1×
“The SBGN model was translated into Systems Biology Markup Language (SBML), a simple and well known XML-based language, which adds components that reflect the natural conceptual constructs used by Systems Biology modelers [44].”
MethodProvenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 2×
“com/oncotarget Other studies showed that the gemcitabine transporter protein hENT1 is associated with the outcome of the disease [32].”
BackgroundFasting: molecular mechanisms and clinical applications
Longo, V. D., & Mattson, M. P. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.008 · Cited by 1,425
Raffaghello, L., Lee, C., Safdie, F. M., Wei, M., Madia, F., Bianchi, G., & Longo, V. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708100105 · Cited by 587 · cited 2×
“Recent studies in rodent and in vitro models uncovered a potential link between short term starvation and improved efficacy of chemotherapy for some types of cancer [13, 14].”
BackgroundMethodTransport properties of pancreatic cancer describe gemcitabine delivery and response
Koay, E. J., Truty, M. J., Cristini, V., Thomas, R. M., Chen, R., Chatterjee, D., Kang, Y., Bhosale, P. R., Tamm, E. P., Crane, C. H., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73455 · Cited by 184 · cited 2×
“In fact, Koay et al, demonstrated that tumors displaying higher stromal scores had lower gemcitabine DNA incorporation [28].”
Background
Cited by
Fasting and cancer: molecular mechanisms and clinical application
Nencioni, A., Caffa, I., Cortellino, S., & Longo, V. D. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0061-0 · Cited by 518
Starvation, Stress Resistance, and Cancer
Buono, R., & Longo, V. D. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.01.008 · Cited by 162
Diet-microbiome interactions in cancer
Abdeen, S. K., Mastandrea, I., Stinchcombe, N., Puschhof, J., & Elinav, E. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.013 · Cited by 36
Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels
Panebianco, C., Trivieri, N., Villani, A., Terracciano, F., Latiano, T. P., Potenza, A., Perri, F., Binda, E., & Pazienza, V. (2021) · Biomolecules · doi:10.3390/biom11050639 · Cited by 26
Self-citation
Metadata
- Authors
- D’Aronzo, M., Vinciguerra, M., Mazza, T., Panebianco, C., Saracino, C., Pereira, S. P., Graziano, P., & Pazienza, V.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-05-19
- Volume
- 6
- Issue
- 21
- Pages
- 18545-18557
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1493806409
- Cited by
- 87
- References
- 5
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. https://app.cochat.ai/papers/10.18632/oncotarget.4186
- The paper
- D’Aronzo, M., Vinciguerra, M., Mazza, T., Panebianco, C., Saracino, C., Pereira, S. P., Graziano, P., & Pazienza, V. (2015). Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. Oncotarget. https://doi.org/10.18632/oncotarget.4186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.